ACE2 and COVID-19: In vitro, ACE2-EVs from COVID-19 patients’ plasma and ACE2-EVs released by the ACE-2 expressing human lung epithelial cell line Calu-3 inhibit SARS-CoV-2 and VOC infections with greater efficacy than soluble ACE-2.